Close
Close
Finance News

Arrowhead Pharmaceuticals Announces Proposed Underwritten Offering of Common Stock

3.16666666667
3.2 from 6 votes
Thursday, January 18, 2018

PASADENA, Calif. - Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) announced its intention to offer and sell shares of its common stock in an underwritten offering pursuant to its existing shelf registration statement. All of the shares in the proposed offering are to be sold by Arrowhead.

Jefferies LLC and Barclays Capital Inc. are acting as bookrunnning managers for the offering, and Cantor Fitzgerald & Co. is acting as passive joint bookrunner for the offering. Arrowhead intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

A shelf registration statement on Form S-3 (File No. 333-214315) relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the "SEC") and is effective. A preliminary prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. When available, copies of the preliminary prospectus supplement may also be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by e-mail at Prospectus_Department@Jefferies.com or from Barclays Capital Inc., Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, telephone: 1-888-603-5847, or email: Barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

Contacts:

Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
Phone: 626-304-3400
Email: ir@arrowheadpharma.com
or
Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
Phone: 212-915-2578
Email: britchie@lifesciadvisors.com

Source: Arrowhead Pharmaceuticals, Inc.
3.16666666667
3.2 from 6 votes
Free Newsletter
Videos